What year was the pharmaceutical company that markets Mylotarg purchased by Pfizer?
Gemtuzumab ozogamicin Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. It was re-introduced into the US market in 2017.
Diversified Pharmaceutical Services Diversified Pharmaceutical Services entered the market in 1976 as the pharmacy benefit manager for United HealthCare (now United HealthGroup), a leading national managed care organization. Diversified pioneered many cost containment strategies that are now core pharmacy benefit manager services and became a recognized leader in clinical programs. After its acquisition by SmithKline Beecham in 1994, Diversified played a pivotal role in that company's Healthcare Service division. Express Scripts acquired Diversified April 1, 1999 and consolidated its position as a leading PBM for managed care organizations.